Advancing the development of interchangeable biosimilars and reducing or developing alternatives to clinical studies involving human subjects have been highlighted as the key priorities for a US Food and Drug Administration regulatory science pilot program under the third iteration of the Biosimilar User Fee Amendments, in a detailed new document released by the agency.
In the “Research Roadmap” document that has
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?